NCT07213518

Brief Summary

compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1 respiratory failure

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
108

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

October 2, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 9, 2025

Completed
Last Updated

October 9, 2025

Status Verified

October 1, 2025

Enrollment Period

6 months

First QC Date

October 2, 2025

Last Update Submit

October 2, 2025

Conditions

COVID-19 Pneumonia

Keywords

High Velocity Nasal InsufflationAcute Type 1 Respiratory FailureCOVID 19 Pneumonic PatientsContinuous Positive Airway Pressure

Outcome Measures

Primary Outcomes (1)

  • Correction of hypoxia in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure

    assessment of efficacy of High Velocity Nasal Insufflation versus Continuous Positive Airway Pressure in COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure

    6 months

Study Arms (2)

Continuous Positive Airway Pressure

ACTIVE COMPARATOR

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous Positive Airway Pressure

Device: Continuous Positive Airway Pressure

High Velocity Nasal Insufflation

ACTIVE COMPARATOR

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity Nasal Insufflation

Device: High Velocity Nasal Insufflation

Interventions

High Velocity Nasal InsufflationDEVICE

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity Nasal Insufflation

High Velocity Nasal Insufflation
Continuous Positive Airway PressureDEVICE

COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous Positive Airway Pressure

Continuous Positive Airway Pressure

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory failure were included.

You may not qualify if:

  • patients with hypercapnic respiratory failure.
  • patients with a disturbed level of consciousness and/or a high risk of aspiration
  • individuals with hypotension
  • patients requiring invasive mechanical ventilation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mohamed AbdElmoniem

Al Mansurah, 35516, Egypt

Location

MeSH Terms

Conditions

Respiratory Insufficiency

Interventions

Continuous Positive Airway Pressure

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Positive-Pressure RespirationRespiration, ArtificialAirway ManagementTherapeuticsRespiratory Therapy

Study Officials

  • Mohamed AbdElmoniem

    Lecturer of chest medicine faculty of medicine Mansoura university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 2, 2025

First Posted

October 9, 2025

Study Start

January 1, 2022

Primary Completion

July 1, 2022

Study Completion

January 1, 2023

Last Updated

October 9, 2025

Record last verified: 2025-10

Locations

EG(1)